Table 2.
Antibody response by treatment group in the modified intent-to-treat population
| Antibody Specificity | Statistic | SeVRSV Group (N = 17) |
Placebo Group (N = 4) |
|---|---|---|---|
| SeV | GMFRa | 2.04 | 0.96 |
| 95% CI | 1.52, 2.75 | 0.83, 1.11 | |
| % with 4-Fold Riseb | 18 | 0 | |
| 95% CI | 6, 41 | 0, 49 | |
| RSV F | GMFRa | 1.08 | 0.97 |
| 95% CI | 1.04, 1.11 | 0.79, 1.20 | |
| % with 4-Fold Riseb | 0 | 0 | |
| 95% CI | 0, 18 | 0, 49 | |
| SeV Day 0 (Pre-Vaccination) | GMTc | 485 | 202 |
| 95% CI | 317, 741 | 49, 836 | |
| SeV Day 28 Post -Vaccination | GMTc | 989 | 194 |
| 95% CI | 736,1329 | 42, 895 | |
| RSV F Day 0 (Pre-Vaccination) | GMTc | 5763 | 4895 |
| 95% CI | 4230, 7852 | 907, 26416 | |
| RSV F Day 28 Post -Vaccination | GMTc | 6194 | 4760 |
| 95% CI | 4529, 8470 | 979, 23154 |
The geometric mean fold rise (GMFR)a, the percentage of participants achieving a four-fold rise in antibodies between baseline sampling and day 28b, and the geometric mean titer (GMT)c were calculated.